ISSN: 2212-3970 (Online)
ISSN: 1574-8928 (Print)


Volume 12, 4 Issues, 2017


Download PDF Flyer

http://www.recentpatentsonanticancerdrugdiscovery.com/


Recent Patents on Anti-Cancer Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:

Khurshid Zaman


Bentham Science Publishers
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.956
5 - Year: 2.899
Browse Contents
Select Volume:


Select Issue:


Select Article:


Abstracted/Indexed in




Endorsement(s)

"The new journal on Recent Patents on Anti-Cancer Drug Discovery is an important patent journal in the field of Anti-Cancer Drug Discovery, which should provide research scientists in the field with recent developments in various frontier areas. The journal is strongly recommended to the scientific community."

Robert Huber
Nobel Laureate

Forthcoming Special Issue(s)

Metabolic Targeting of Cancers


Guest Editor(s): Hongbin Sun, Huaming Sheng
Tentative Publication Date: January, 2016
Submit Abstract via Email Download Description
Authors' Comments
Thank you for your email. We are pleased to be the part of bentham science publishers through this esteemed journal. We wish to thank the editorial team and the reviewers for their excellent efforts in the improvement of our manuscript. It will be our great pleasure to recommend the journal to other researchers working in this area.

Arunaksharan Narayanankutty
(Department of Biochemistry, Amala Cancer Research Centre, Thrissur, Kerala, India)



Recent Patents on Anti-Cancer Drug Discovery

,

Volume 12

-

Number 4



Review Article

Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs

, 12(4): 296 - 322

Qing-Yuan Lan, Yan-Le Zhi, Hao Heng, Jie-Yi Tian, Xiao-Xing Guo, Hai-Chun Liu, Ya-Dong Chen, Tao Lu* and Shuai Lu*


DOI: 10.2174/1574892812666170727154643
Abstract PubMed Reprints Eprints Permissions




Advances In the Discovery of Anthraquinone-Based Anticancer Agents


Alexander Tikhomirov*, Alexander Shtil and Andrey Shchekotikhin


View Abstract



PARP inhibitors in epithelial ovarian cancer


Kristin N. Taylor and Ramez N. Eskander*


View Abstract



Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins


Federica Iannelli, Rita Lombardi, Maria Rita Milone, Biagio Pucci, Simona De Rienzo, Alfredo Budillon and Francesca Bruzzese*


View Abstract



Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents

, 2017; 12(3): 190 - 207

Stephanie Lucas, Claire Soave, Ghazal Nabil, Zainab Sabry Othman Ahmed, Guohua Chen, Hossny Awad El-Banna, Q. Ping Dou* and Jian Wang*


DOI: 10.2174/1574892812666170619125503
Abstract PubMed Reprints Eprints Permissions



Recent Patents on Proteasome Inhibitors of Natural Origin

, 2017; 12(1): 4 - 15

Daniela Correia da Silva, Paula B. Andrade, Vera Ribeiro, Patricia Valentao and David M. Pereira


DOI: 10.2174/1574892812666161123142037
Abstract PubMed Reprints Eprints Permissions



HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer

, 2016; 11(4): 434 - 443

Maryam Iman, Seyede Samaneh Mostafavi, Seyed Shahriar Arab, Sadegh Azimzadeh and Mansour Poorebrahim


DOI: 10.2174/1574892811999160628114857
Abstract Reprints Eprints Permissions



Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science